Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Futibatinib + Pelitinib |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Futibatinib | Lytgobi | TAS-120 | FGFR Inhibitor (Pan) 26 | Lytgobi (futibatinib) is a third-generation pan-FGFR inhibitor, which results in the inhibition of FGFR-mediated signal transduction pathways and tumor cell proliferation (PMID: 31109923). Lytgobi (futibatinib) is FDA approved for use in patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 fusion or rearrangement (FDA.gov). |
| Pelitinib | EKB-569|WAY-EKB 569 | EGFR Inhibitor (Pan) 63 HER2 Inhibitor 44 | Pelitinib (EKB-569) is a nonselective inhibitor of EGFR, ERBB2 (HER2), and ERBB4 (HER4), which induces apoptosis and inhibits cell proliferation (PMID: 25988710). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|